![]() ![]() Bradway, chairperson and CEO of Amgen, said in the release. “The acquisition of Horizon is a compelling opportunity for Amgen and one that is consistent with our strategy of delivering long-term growth by providing innovative medicines that address the needs of patients who suffer from serious diseases,” Robert A. Horizon, based in Dublin, has 12 marketed medicines and a pipeline with more than 20 development programs, according to a press release from Amgen. If you continue to have this issue please contact to HealioĪmgen Inc., which has established its mark in kidney care as the dominant supplier of anemia treatments, agreed to buy Ireland-based Horizon Therapeutics plc for $28.3 billion in a cash offer. ![]() Nuvig is building a pipeline of novel immune therapeutics for chronic inflammatory and autoimmune diseases.Ĭorporate: Julie Anne Smith, CEO, Nuvig Therapeutics, Inc., Jessica Yingling, Ph.D., Little Dog Communications Inc., +1. were unable to process your request. Nuvig Therapeutics is advancing innovative and transformational therapies that are designed to induce natural mechanisms to restore immune homeostasis, rebalance immune function following inflammation, and improve the treatment options for patients. Smith serves as a director on the Boards of Exelixis (Nasdaq: EXEL) and Stoke Therapeutics (Nasdaq: STOK). Earlier in her career, she held roles at Jazz Pharmaceuticals, Genzyme, Novazyme, and Bristol-Myers Squibb. Smith also served as Chief Commercial Officer of Enobia Pharmaceuticals until it was acquired by Alexion Pharmaceuticals. She previously served as President and CEO of Raptor Pharmaceuticals, which developed and commercialized therapies for the orphan disease nephropathic cystinosis and chronic pulmonary infections before its acquisition by Horizon Pharmaceuticals. Smith served as President and CEO of ESCAPE Bio, a biotech company developing precisely targeted therapies for genetic forms of neurodegeneration. “I look forward to working with Pam and the team to propel our development candidates into the clinic with the goal of providing new therapeutic options for autoimmune diseases without broad immunosuppression.” “I’m delighted to join Nuvig at this pivotal time as the team has received strong investor support and rapidly advanced its novel technology to the IND-enabling stage,” said Ms. Nuvig is extending this technology to build a pipeline of differentiated protein therapeutics that can be used in the context of varied but well-defined inflammatory and autoimmune diseases. Nuvig’s lead program is a novel recombinant human antibody fragment engineered to induce immune modulatory mechanisms that restore immune homeostasis and control inflammation in autoimmune diseases. “We are excited by the dynamic leadership, vision, and experience Julie brings to the company and look forward to working closely with her to advance Nuvig’s therapies to patients.” “The board is very grateful to Pam for leading Nuvig from inception to this exciting inflection point, as the company enters IND-enabling activities for its lead program,” said Kenneth Harrison, Ph.D., Director of Nuvig Therapeutics and Partner at Novo Ventures. Pamela Conley, Ph.D., cofounder and founding CEO of Nuvig Therapeutics, will serve as the Company’s Chief Scientific Officer. Smith has over 20 years of experience in the life science industry, with a focus on leading private and public biotech companies through development and commercialization of therapeutics for orphan diseases. Redwood City, Calif., Janu– Nuvig Therapeutics, Inc., a biopharma company developing proprietary recombinant human therapeutics for patients with autoimmune diseases, today announced the appointment of Julie Anne Smith as Chief Executive Officer (CEO) and member of the Board of Directors. ![]()
0 Comments
Leave a Reply. |
Details
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |